STOCK-BASED COMPENSATION AND OTHER BENEFIT PLANS (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]

Schedule of Stock-Based Compensation

	Year Ended December 31,
	2025		2024		2023
	(in thousands)
Stock-based compensation - equity awards	$	5,954	$	4,567	$	3,338
Stock-based compensation - liability awards	—		(9)		(15)
Total stock-based compensation	$	5,954	$	4,558	$	3,323

Schedule of Weighted Average Grant Date Fair Value of Performance Stock Options Grants

During the year ended December 31, 2025, the weighted average assumptions shown below were used to calculate the weighted average grant date fair value of the PSS awards under the Monte Carlo model.

	Year Ended December 31,
	2025
Average expected volatility	68.71		%
Risk-free interest rate	4.40		%
Expected dividend yield	7.44		%
Weighted average grant date fair value - ($/share)	$	2.29

During the year ended December 31, 2024 and 2023 the weighted average assumptions shown below were used to calculate the weighted average grant date fair value of performance stock options grants under the Monte Carlo model.

	Year Ended December 31,
	2024			2023
Weighted average exercise price - ($/share)	$	5.96		$	4.19
Expected life in years	6.7			6.4
Average expected volatility	71		%	68		%
Risk-free interest rate	4.28		%	3.73		%
Expected dividend yield	4.19		%	5.97		%
Weighted average grant date fair value - ($/share)	$	3.27		$	2.29

Schedule of Nonvested Performance-Based Units Activity

PSS awards activity associated with the Monte Carlo model for the year ended December 31, 2025 is provided below:

	Number of Shares Underlying Options	Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term
	(in thousands)			(in years)
Unvested at January 1, 2025	—	$	—
Granted	790	2.29
Unvested at December 31, 2025	790	$	2.29	1.75

Schedule of Performance Stock Options Activity

Performance stock options activity associated with the Monte Carlo model for the year ended December 31, 2025 is provided below:

	Number of Shares Underlying Options	Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
	(in thousands)			(in years)	(in thousands)
Outstanding at January 1, 2025	1,118	$	5.32
Unvested shares forfeited	(21)	6.41
Outstanding at December 31, 2025	1,097	$	5.30	7.6	$	79
Exercisable at December 31, 2025	333	$	4.21	6.8	$	79

Schedule of Restricted Stock Activity

The following is the activity for the Company's restricted stock for the year ended December 31, 2025:

	Restricted Stock	Weighted Average Grant Date Fair Value
	(in thousands)
Non-vested shares outstanding at January 1, 2025	1,352	$	5.41
Awards granted	1,461	3.36
Awards vested	(623)	5.39
Awards forfeited	(226)	4.15
Non-vested shares outstanding at December 31, 2025	1,964	$	4.03

RSU activity for the year ended December 31, 2025 is presented in the table below:

	Restricted Stock	Weighted Average Conversion Date Fair Value
	(in thousands)
Non-vested shares outstanding at January 1, 2025	174	$	5.01
Awards granted	331	3.36
Awards vested	(82)	4.78
Awards forfeited	(17)	3.36
Non-vested shares outstanding at December 31, 2025	406	$	3.79

Schedule of Performance Activity

PSU activity for the year ended December 31, 2025 is presented in the table below:

	Restricted Stock	Weighted Average Conversion Date Fair Value
	(in thousands)
Non-vested shares outstanding at January 1, 2025	9	$	4.27
Awards vested	(9)	4.27
Non-vested shares outstanding at December 31, 2025	—	$	—